Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date
Mandate

Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date

June 08, 2023 Employment and Benefits Banking and Finance Corporate Tax Private Funds M&A

The fund – which is Fidelio Capital’s third – has secured more than EUR 1 billion in total capital commitments from an international investor base, which is more than triple the size of the total capital commitments of its previous investment mandate.

Fidelio Capital was founded by Gabriel Fitzgerald in 2010 and focuses on investments in companies without being limited by a pre-determined investment horizon or geographical border, in which it can be an active owner. Through its investment strategy, Fidelio Capital has generated market leading returns, with an average gross IRR of 80% since inception.

Vinge’s team primarily consisted of Mattias Schömer, Jonas Bergström, Jesper Ottergren, Martin Cronsioe, Viveka Classon, Malin Malm Waerme, Fredrik Dahl, Anton Sjökvist, Emelie Svanberg, Semir Omerbasic and Viktoria Wnuk.

 

Related

Vinge advises Spetses Investments and Bacara Holdings on the public offer for IRRAS

 A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
October 03, 2023

Vinge advises SAGA Diagnostics AB on convertible note issue

 SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

 Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023